Wells Fargo & Company MN Has $128,000 Stock Holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Wells Fargo & Company MN lowered its holdings in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) by 74.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 27,506 shares of the company’s stock after selling 81,454 shares during the period. Wells Fargo & Company MN’s holdings in GoodRx were worth $128,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. National Bank of Canada FI raised its stake in GoodRx by 34.9% during the fourth quarter. National Bank of Canada FI now owns 8,308 shares of the company’s stock worth $39,000 after acquiring an additional 2,151 shares in the last quarter. RPO LLC acquired a new stake in GoodRx in the fourth quarter valued at approximately $52,000. Versor Investments LP bought a new stake in shares of GoodRx during the fourth quarter worth $54,000. Verus Capital Partners LLC acquired a new position in shares of GoodRx during the fourth quarter worth $55,000. Finally, Steward Partners Investment Advisory LLC bought a new position in shares of GoodRx in the 4th quarter valued at $56,000. 63.77% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have issued reports on GDRX shares. The Goldman Sachs Group lowered their target price on GoodRx from $6.00 to $5.00 and set a “neutral” rating for the company in a report on Friday. Truist Financial reduced their price target on GoodRx from $6.50 to $5.50 and set a “hold” rating on the stock in a report on Thursday, April 10th. Finally, Wells Fargo & Company reduced their target price on shares of GoodRx from $8.00 to $7.00 and set an “overweight” rating on the stock in a report on Tuesday, April 29th. Five analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $7.60.

GoodRx Price Performance

Shares of NASDAQ GDRX opened at $4.36 on Friday. GoodRx Holdings, Inc. has a twelve month low of $3.68 and a twelve month high of $9.26. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. The firm has a fifty day simple moving average of $4.49 and a 200 day simple moving average of $4.73. The company has a market capitalization of $1.67 billion, a PE ratio of -145.33, a P/E/G ratio of 2.46 and a beta of 1.24.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.05. GoodRx had a negative net margin of 2.05% and a positive return on equity of 5.35%. The firm had revenue of $202.97 million during the quarter, compared to the consensus estimate of $202.25 million. During the same period in the previous year, the firm posted $0.08 earnings per share. The business’s revenue was up 2.6% compared to the same quarter last year. On average, sell-side analysts forecast that GoodRx Holdings, Inc. will post 0.13 EPS for the current year.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.